EA200500218A1 - ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ С ПРИМЕНЕНИЕМ ИНТЕРФЕРОНА-β - Google Patents

ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ С ПРИМЕНЕНИЕМ ИНТЕРФЕРОНА-β

Info

Publication number
EA200500218A1
EA200500218A1 EA200500218A EA200500218A EA200500218A1 EA 200500218 A1 EA200500218 A1 EA 200500218A1 EA 200500218 A EA200500218 A EA 200500218A EA 200500218 A EA200500218 A EA 200500218A EA 200500218 A1 EA200500218 A1 EA 200500218A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
interferon
kidney insufficiency
insufficiency
kidney
Prior art date
Application number
EA200500218A
Other languages
English (en)
Other versions
EA009938B1 (ru
Inventor
Рой Р. Лобб
Original Assignee
Байоджен Айдек Ма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен Айдек Ма Инк. filed Critical Байоджен Айдек Ма Инк.
Publication of EA200500218A1 publication Critical patent/EA200500218A1/ru
Publication of EA009938B1 publication Critical patent/EA009938B1/ru

Links

Classifications

    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L47/00—Traffic control in data switching networks
    • H04L47/50—Queue scheduling
    • H04L47/62—Queue scheduling characterised by scheduling criteria
    • H04L47/6285—Provisions for avoiding starvation of low priority queues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L47/00—Traffic control in data switching networks
    • H04L47/10—Flow control; Congestion control
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L47/00—Traffic control in data switching networks
    • H04L47/10—Flow control; Congestion control
    • H04L47/215—Flow control; Congestion control using token-bucket
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W28/00—Network traffic management; Network resource management
    • H04W28/02—Traffic management, e.g. flow control or congestion control
    • H04W28/0252—Traffic management, e.g. flow control or congestion control per individual bearer or channel
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W28/00—Network traffic management; Network resource management
    • H04W28/02—Traffic management, e.g. flow control or congestion control
    • H04W28/0278—Traffic management, e.g. flow control or congestion control using buffer status reports
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W72/00—Local resource management
    • H04W72/20—Control channels or signalling for resource management
    • H04W72/23—Control channels or signalling for resource management in the downlink direction of a wireless link, i.e. towards a terminal
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W8/00—Network data management
    • H04W8/02—Processing of mobility data, e.g. registration information at HLR [Home Location Register] or VLR [Visitor Location Register]; Transfer of mobility data, e.g. between HLR, VLR or external networks
    • H04W8/04—Registration at HLR or HSS [Home Subscriber Server]
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W72/00—Local resource management
    • H04W72/12—Wireless traffic scheduling

Abstract

В настоящем изобретении предлагаются способы лечения и фармацевтические агенты для применения в лечении млекопитающих субъектов, имеющих гломерулонефрит или хроническую почечную недостаточность или риск их развития. Способы включают введение терапевтических агентов, содержащих ИФН-β.
EA200500218A 2002-07-17 2003-07-17 ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ С ПРИМЕНЕНИЕМ ИНТЕРФЕРОНА-β EA009938B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39639302P 2002-07-17 2002-07-17
PCT/US2003/022440 WO2004006756A2 (en) 2002-07-17 2003-07-17 THERAPIES FOR RENAL FAILURE USING INTERFERON-β

Publications (2)

Publication Number Publication Date
EA200500218A1 true EA200500218A1 (ru) 2006-08-25
EA009938B1 EA009938B1 (ru) 2008-04-28

Family

ID=30116023

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500218A EA009938B1 (ru) 2002-07-17 2003-07-17 ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ С ПРИМЕНЕНИЕМ ИНТЕРФЕРОНА-β

Country Status (20)

Country Link
US (1) US20070025965A1 (ru)
EP (1) EP1553971A4 (ru)
JP (2) JP4883665B2 (ru)
KR (2) KR20110053390A (ru)
CN (2) CN101664545A (ru)
AU (1) AU2003256603C1 (ru)
BR (1) BR0312947A (ru)
CA (1) CA2492649A1 (ru)
EA (1) EA009938B1 (ru)
GE (1) GEP20084499B (ru)
IL (2) IL166256A (ru)
IS (1) IS7650A (ru)
MX (1) MXPA05000658A (ru)
NO (1) NO20050827L (ru)
NZ (1) NZ538217A (ru)
PL (1) PL374914A1 (ru)
RS (1) RS20050035A (ru)
UA (1) UA88440C2 (ru)
WO (1) WO2004006756A2 (ru)
ZA (1) ZA200500342B (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0517701A8 (pt) 2004-11-10 2018-01-23 Genzyme Corp métodos de tratamento de diabetes mellitus
EP1917276B1 (en) 2005-08-26 2018-03-21 Ares Trading S.A. Process for the preparation of glycosylated interferon beta
AU2006323925B2 (en) 2005-12-09 2012-08-02 Ares Trading S.A. Method for purifying FSH or a FSH mutant
US7553941B2 (en) * 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
ES2546181T3 (es) 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
KR101532369B1 (ko) * 2006-12-11 2015-06-29 삼성전자주식회사 휴대용 단말기의 원격제어 장치 및 방법
WO2008150486A2 (en) 2007-05-31 2008-12-11 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
WO2009045503A1 (en) 2007-10-05 2009-04-09 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
AU2008314687A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying Fc-fusion proteins
EP3595264B1 (en) * 2007-10-27 2021-04-07 BlackBerry Limited Content disposition system and method for processing message content in a distributed environment
WO2009080699A2 (en) * 2007-12-20 2009-07-02 Merck Serono S.A. Peg-interferon-beta formulations
US8389517B2 (en) * 2008-07-28 2013-03-05 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
EP2349255B1 (en) 2008-10-03 2016-03-30 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US9913880B2 (en) * 2011-02-18 2018-03-13 Stemdr Inc. Method of treating sepsis or septic shock
CN104487082A (zh) 2012-04-19 2015-04-01 奥普科生物制品有限公司 长效胃泌酸调节素变体及其生产方法
BR122020018510B1 (pt) 2012-11-20 2023-03-14 Opko Biologics Ltd Método para aumentar incrementalmente o tamanho hidrodinâmico de um fator de coagulação ativado viia
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
WO2016203482A2 (en) 2015-06-19 2016-12-22 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
FI126979B (en) 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and use thereof
HUE064463T2 (hu) 2016-07-11 2024-03-28 Opko Biologics Ltd Hosszantartó hatású VII. koagulációs faktor és az elõállítására vonatkozó eljárások
RU2728696C2 (ru) * 2018-12-28 2020-07-30 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Моноклональное антитело к интерферону бета-1а человека

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0797998A4 (en) * 1995-11-17 2003-01-15 Toray Industries PROTECTION FOR ENDOTHEL CELLS
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
PL200586B1 (pl) * 1998-10-16 2009-01-30 Biogen Idec Inc Polipeptydy zawierające mutanty interferonu-beta-1a, kodujące je cząsteczki kwasów nukleinowych, komórki gospodarza transformowane tymi cząsteczkami, sposób wytwarzania polipeptydów, zawierające je kompozycje farmaceutyczne i zastosowania polipeptydów
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US6908611B2 (en) * 2001-06-11 2005-06-21 Transition Therapeutics Inc. Combination therapies using vitamin B12 and interferon for treatment of viral, proliferative and inflammatory diseases

Also Published As

Publication number Publication date
WO2004006756A3 (en) 2004-08-19
US20070025965A1 (en) 2007-02-01
MXPA05000658A (es) 2005-08-19
EA009938B1 (ru) 2008-04-28
WO2004006756A2 (en) 2004-01-22
AU2003256603C1 (en) 2010-07-15
ZA200500342B (en) 2006-07-26
KR20050021502A (ko) 2005-03-07
JP2005537269A (ja) 2005-12-08
EP1553971A4 (en) 2006-07-05
GEP20084499B (en) 2008-10-10
PL374914A1 (en) 2005-11-14
JP2011144204A (ja) 2011-07-28
RS20050035A (en) 2007-06-04
IS7650A (is) 2005-01-14
EP1553971A2 (en) 2005-07-20
CN101664545A (zh) 2010-03-10
IL200892A (en) 2014-11-30
AU2003256603A1 (en) 2004-02-02
CN1681527A (zh) 2005-10-12
KR20110053390A (ko) 2011-05-20
JP4883665B2 (ja) 2012-02-22
IL200892A0 (en) 2010-05-17
UA88440C2 (ru) 2009-10-26
IL166256A0 (en) 2006-01-15
CA2492649A1 (en) 2004-01-22
NO20050827L (no) 2005-04-15
AU2003256603B2 (en) 2009-07-30
BR0312947A (pt) 2007-07-10
NZ538217A (en) 2007-04-27
IL166256A (en) 2010-11-30

Similar Documents

Publication Publication Date Title
EA200500218A1 (ru) ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ С ПРИМЕНЕНИЕМ ИНТЕРФЕРОНА-β
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
PL371736A1 (en) Method for administering glp-1 molecules
TR200000913T2 (tr) Tıbbi maddeler
NO20044462L (no) Anvendelse av EP4-reseptorligander i behandling av IL-6 involverte sykdommer
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
DK1465688T3 (da) Bicarbonat-baserede opløsninger til dialyseterapi
HUP0103484A2 (hu) Anti-CD20-ellenanyag alkalmazása B-sejtes limfómák kombinációs terápiájára
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
DK1503788T3 (da) Behandling af alpha-galactosidase A-deficiens
MXPA04006572A (es) Terapia de combinacion antivirica.
NO20052059L (no) Terapier for kronisk inflammatorisk demyeliniserende polynevropati ved anvendelse av interferon-beta.
DK1411064T3 (da) Gangliosid-associerede rekombinante antistoffer og anvendelsen deraf i diagnosen og behandlingen af tumorer
TR200200112T2 (tr) Fosfat taşıma ihtibitörleri
EA200600468A1 (ru) Биполярные транс-каротиноидные соли и их применение
DK1418905T3 (da) Terapeutisk middel til depletering af en uönsket proteinpopulation fra plasma
CY1106950T1 (el) Μονοενυδρο αλας νατριου της s-tενατοπραζολης και εφαρμογη υπο τυπον αναστολεα αντλιας πρωτονιων
EA200500774A1 (ru) Новая синергетическая комбинация, включающая рофлумиласт и формотерол
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
CY1105117T1 (el) Θepαπειες για τη χρονια νεφρικη ανεπαρκεια χρησιμοποιωντας ανταγωνιστες των ενσωματινων
ATE369147T1 (de) Verwendung von stimulierten mononuklearen zellen des peripheren blutes zur behandlung von krebserkrankungen
EA200401454A1 (ru) Новая комбинация из обратимо действующих ингибиторов протонного насоса и используемых в терапии дыхательных путей лекарственных веществ, предназначенных для лечения респираторных заболеваний
EA200971092A1 (ru) Vegf-d мутанты и их применение
DE60317015D1 (de) Hämokonzentrator in einem extrakorporalen Blutkreislauf
ATE414776T1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU